CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Toxicity of kadsura coccinea (Lem.) A. C. Sm. essential oil to the bed bug, cimex lectularius L. (hemiptera: Cimicidae)
Authors
Amar G. Chittiboyina
Ikhlas A. Khan
+7 more
Bin Li
Yongbei Liu
Yan Qin
Junaid U. Rehman
Mei Wang
Wei Wang
Yupei Yang
Publication date
1 June 2019
Publisher
eGrove
Abstract
Copyright © 2019 American Society for Microbiology. All Rights Reserved. We sought to define trends in and predictors of carbapenem consumption across community, teaching, and university-affiliated hospitals in the United States and Canada. We conducted a retrospective multicenter survey of carbapenem and broad-spectrum noncarbapenem beta-lactam consumption between January 2011 and December 2013. Consumption was tabulated as defined daily doses (DDD) or as days of therapy (DOT) per 1,000 patient days (PD). Multivariate mixed-effects models were explored, and final model goodness of fit was assessed by regressions of observed versus predicted values and residual distributions. A total of 20 acute-care hospitals responded. The centers treated adult patients (n 19/20) and pediatric/neonatal patients (n 17/20). The majority of the centers were nonprofit (n 17/20) and not affiliated with medical/teaching institutions (n 11/20). The median (interquartile range [IQR]) carbapenem consumption rates were 38.8 (17.4 to 95.7) DDD/1,000 PD and 29.7 (19.2 to 40.1) DOT/1,000 PD overall. Carbapenem consumption was well described by a multivariate linear mixed-effects model (fixed effects, R2 0.792; fixed plus random effects, R2 0.974). Carbapenem consumption increased by 1.91-fold/quarter from 48.6 DDD/1,000 PD (P 0.004) and by 0.056-fold/quarter from 45.7 DOT/ 1,000 PD (P 0.93) over the study period. Noncarbapenem consumption was independently related to increasing carbapenem consumption (beta 0.31 for increasing noncarbapenem beta-lactam consumption; P 0.001). Regular antibiogram publication and promotion of conversion from intravenous (i.v.) to oral (p.o.) administration independently affected carbapenem consumption rates. In the final model, 58.5% of the observed variance in consumption was attributable to between-hospital differences. Rates of carbapenem consumption across 20 North American hospitals differed greatly, and the observed differences were correlated with hospital-specific demographics. Additional studies focusing on the drivers of hospital-specific carbapenem consumption are needed to determine whether these rates are justifiable
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
eGrove (Univ. of Mississippi)
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:egrove.olemiss.edu:pharmac...
Last time updated on 16/04/2021